Effect of supplementation in treatment of patients with multiple sclerosis

Clinical trial of the effect of probiotic supplementation compared with the placebo on levels of gene expression related with glycemic control, lipid and inflammatory factors in patients with multiple sclerosis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201609185623N88

Enrollment

Registered

2016-09-27

Start date

2016-07-24

Completion date

Unknown

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis. Multiple sclerosis

Interventions

Intervention 1: Control group: Placebo (Barij Essence, Kashan, Iran), daily, for 12 weeks orally. Intervention 2: Intervention group: Probiotic capsule containing four strains of Lactobacillus acidoph

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Patients with multiple sclerosis Aged 18 to 55 years Course of disease relapsing–remitting MS (RRMS) EDSS =4.5

Exclusion criteria

Exclusion criteria: Pregnancy Women who were lactating within the prior six month Consumption of of probiotic or synbiotic Menopaused women with irregular menstruation Unwillingness to utilize appropriate contraceptive tools

Design outcomes

Primary

Measure	Time frame
Tumor necrosis factor alpha. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Interleukin 1. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Interleukin-8. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.	—

Secondary

Measure	Time frame
Peroxisome proliferator–activated receptor ? (PPAR?). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Low Density Lipoprotein Receptor (LDLR). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_z@kaums.ac.ir+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026